Association of chemosensory dysfunction and COVID‐19 in patients presenting with influenza‐like symptoms

Yan, Carol H.; Faraji, Farhoud; Prajapati, Divya P.; Boone, Christine; DeConde, Adam S.

doi:10.1002/alr.22579

Cited by 719 publications

(1,003 citation statements)

References 8 publications

Supporting

Mentioning

872

Contrasting

Unclassified

Order By: Relevance

“…Their results showed these chemosensory impairments were at least 10-fold more common in COVID-19-positive cases than COVID-19-negative cases, both presenting with similar influenza-like symptoms. 26 While the authors of this study did not reveal how many of these patients tested positive for influenza virus, 26 past studies have demonstrated that influenza is not significantly associated with change in smell. 27 Furthermore, postviral olfactory disorders due to other common viruses has an estimated prevalence of around 11%-40%, 28 which appears much less common than that seen with SARS-CoV-2 infection according to existing studies.…”

Section: Unusual Association Of Diseases/symptoms Patient's Perspectivementioning

confidence: 64%

Hypogeusia as the initial presenting symptom of COVID-19

2020

View full text Add to dashboard Cite

COVID-19 is the disease caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first arose in Wuhan, China, in December 2019 and has since been declared a pandemic. The clinical sequelae vary from mild, self-limiting upper respiratory infection symptoms to severe respiratory distress, acute cardiopulmonary arrest and death. Otolaryngologists around the globe have reported a significant number of mild or otherwise asymptomatic patients with COVID-19 presenting with olfactory dysfunction. We present a case of COVID-19 resulting in intensive care unit (ICU) admission, presenting with the initial symptom of disrupted taste and flavour perception prior to respiratory involvement. After 4 days in the ICU and 6 days on the general medicine floor, our patient regained a majority of her sense of smell and was discharged with only lingering dysgeusia. In this paper, we review existing literature and the clinical course of SARS-CoV-2 in relation to the reported symptoms of hyposmia, hypogeusia and dysgeusia.

show abstract

Section: Unusual Association Of Diseases/symptoms Patient's Perspectivementioning

confidence: 64%

Hypogeusia as the initial presenting symptom of COVID-19

2020

View full text Add to dashboard Cite

show abstract

“…The majority of our cohort do meet current criteria for testing in the UK, as it is only being undertaken in hospitalised patients, however, of those tested in our survey, 80% were found to be positive, While we do not know the means of testing, but in most cases, RT-PCR analysis of nasal swabs has been used, which have an estimated sensitivity of 72% [18]. Many patients also reported other symptoms described in COVID-19 infection, with half also reporting a new onset cough or fever, therefore making COVID-19 likely according to the results of Menni et al [12] and Yan et al [13]. However, our assumption that our cohort reflects patients with COVID-19 cannot be proven without test results even though it is supported by the evince base.…”

Section: Discussionmentioning

confidence: 80%

“…The strongest predictor is loss of smell and taste. In a similar study, Yan et al found smell and taste lost were reported by 68 and 71% of COVID positive patients respectively, compared to 16 and 17% of COVID negative patients, with loss of sense of smell being the strongest predictor (OR 10.9 for COVID-19 positivity) [13].…”

Section: Discussionmentioning

confidence: 83%

Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study

Hopkins

Šurda

Whitehead³

et al. 2020

Journal of Otolaryngology - Head & Neck Surgery

279

285

View full text Add to dashboard Cite

Background: A rapidly evolving evidence suggests that smell and taste disturbance are common symptoms in COVID-19 infection. As yet there are no reports on duration and recovery rates. We set out to characterise patients reporting new onset smell and taste disturbance during the COVID-19 pandemic and report on early recovery rates. Methods: Online Survey of patients reporting self-diagnosed new onset smell and taste disturbance during the COVID-19 pandemic, with 1 week follow-up. Results: Three hundred eighty-two patents completed bot an initial and follow-up survey. 86.4% reported complete anosmia and a further 11.5% a very severe loss of smell at the time of completing the first survey. At follow-up 1 week later, there is already significant improvement in self-rating of severity of olfactory loss. 80.1% report lower severity scores at follow-up, 17.6% are unchanged and 1.9% are worse. 11.5% already report compete resolution at follow up, while 17.3% report persistent complete loss of smell, with reported duration being 1 to over 4 weeks. This is reflected in the overall cumulative improvement rate of 79% patients overall in the interval between surveys. Conclusions: A review of the growing evidence base supports the likelihood that out cohort have suffered olfactory loss as part of COVID-19 infection. While early recovery rates are encouraging, long term rates will need to be further investigated and there may be an increase in patients with persistent post-viral loss as a result of the pandemic. We further call for loss of sense of smell to be formerly recognised as a marker of COVID-19 infection.

show abstract

“…They concluded that the loss of smell or taste was 10 times more likely from COVID-19 infection than other causes of infection. 7 While the study will print next week in the NEJM, Washington post reported a story of "Healthy people in their 30s and 40s, barely sick with COVID-19, are dying from strokes". The paper mentioned that about a dozen of young strokes form three major hospitals in New York and Boston will report this series next week.…”

mentioning

confidence: 99%

Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management

Zhou

Li²,

Wang

et al. 2020

Stroke Vasc Neurol

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID‐19) has become a global pandemic. COVID-19 runs its course in two phases, the initial incubation phase and later clinical symptomatic phase. Patients in the initial incubation phase often have insidious clinical symptoms, but they are still highly contagious. At the later clinical symptomatic phase, the immune system is fully activated and the disease may enter the severe infection stage in this phase. Although many patients are known for their respiratory symptoms, they had neurological symptoms in their first 1–2 days of clinical symptomatic phase, and ischaemic stroke occurred 2 weeks after the onset of the clinical symptomatic phase. The key is to prevent a patient from progressing to this severe infection from mild infection. We are sharing our experience on prevention and management of COVID-19.

show abstract

Association of chemosensory dysfunction and COVID‐19 in patients presenting with influenza‐like symptoms

Cited by 719 publications

References 8 publications

Hypogeusia as the initial presenting symptom of COVID-19

Hypogeusia as the initial presenting symptom of COVID-19

Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study

Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management

Contact Info

Product

Resources

About